Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy

Clinical Journal of Oncology Nursing

Volumn 12, Issue 5, 2008, Pages 771-776

  Leahy, Yvonne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

BODY COMPOSITION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PRIMARY PREVENTION; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PRIMARY PREVENTION; PROSTATIC NEOPLASMS;

EID: 58149293720     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.771-776     Document Type: Article

References (31)

1. Alberti, K.G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome: A new worldwide definition. Lancet, 366(9491), 1059-1062.
2. American Heart Association. (2008). Heart disease and stroke statistics-2008 update. Dallas, TX: Author
3. Appel, S.J., Jones, E.D., & Kennedy-Malone, L. (2004). Central obesity and the metabolic syndrome: Implications for primary care providers. Journal of the American Academy of Nurse Practitioners, 16(8), 335-342.
4. Barnard, R.J. (2007). Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. American Journal of Clinical Nutrition, 86(3), s889-s893.
5. Bigaard, J., Tjonneland, A., Thomsen, B.L., Overvad, K., Heitmann, B.L., & Sorensen, T.I. (2003). Waist circumference, BMI, smoking, and mortality in middle-aged men and women. Obesity Research, 11(7), 895-903.
6. Braga-Basaria, M., Dobs, A.S., Muller, D.C., Carducci, M.A., John, M., Egan, J., et al. (2006). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Journal of Clinical Oncology, 24(24), 3979-3983.
7. Bratt, O. (2002). Hereditary prostate cancer: Clinical aspects. Journal of Urology, 168(3), 906-913.
8. Chlebowski, R.T., Blackburn, G.L., Thomson, C.A., Nixon, D.W., Shapiro, A., Hoy, M.K., et al. (2006). Dietary fat reduction and breast cancer outcome: Interim efficacy results from the Women's Intervention Nutrition Study. Journal of the National Cancer Institute, 98(24), 1767-1776.
9. Cooperberg, M.R., Grossfeld, G.D., Lubeck, D.P., & Carroll, P.R. (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute, 95(13), 981-989.
10. Davies, B.J., Walsh, T.J., Ross, P.L., Knight, S.J., Sadetsky, N., Carroll, P.R., et al. (2008). Effect of BMI on primary treatment of prostate cancer. Urology, 72(2), 406-411.
11. Eri, L.M., Urdal, P., & Bechensteen, A.G. (1995). Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Journal of Urology, 154(1), 100-104.
12. Ford, E.S., Giles, W.H., & Mokdad, A.H. (2004). Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 27(10), 2444-2449.
13. Hsing, A.W., Sakoda, L.C., & Chua, S. (2007). Obesity, metabolic syndrome, and prostate cancer. American Journal of Clinical Nutrition, 86(3), s843-s857.
14. International Diabetes Federation. (2005). The IDF consensus worldwide definition of the metabolic syndrome. Retrieved January 2, 2008, from http://www.idf.org/webdata/docs/Metac_syndrome_def.pdf
15. Janssen, I., Katzmarzyk, P.T., & Ross, R. (2005). Body mass index is inversely related to mortality in older people after adjustment for waist circumference. Journal of the American Geriatrics Society, 53(12), 2112-2118.
16. Keating, N.L., O'Malley, A.J., & Smith, M.R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24(27), 4448-4456.
17. Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilchto, J., et al. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288(21), 2709-2716.
18. National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in OncologyTM: Prostate cancer [v.1.2008]. Retrieved March 1, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf
19. National Institute of Diabetes and Digestive and Kidney Diseases. (2005). National diabetes statistics fact sheet: General information and national estimates on diabetes in the United States, 2005.
20. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health.
21. Rice, C.A. (2005). Prevention: The most economical way to manage diabetes. Nursing Economics, 23(6), 327-329.
22. Ries, L.A.G., Melbert, D., Krapcho, M., Stinchcomb, D.G., Howlader, N., Horner, M.J., et al. (Eds.). (2007). SEER cancer statistics review, 1975-2005. Retrieved August 6, 2008, from http://seer.cancer.gov/csr/1975_2005
23. Segal, R.J., Reid, R., Chris, S., Proulx, C., Courneya, K., Sigal, R., et al. (2007). Resistance or aerobic exercise in men receiving radiation therapy for prostate cancer: A randomized trial [Abstract 113]. Proceedings of the Prostate Cancer Symposium, American Society of Clinical Oncology, Orlando, FL. Retrieved May 9, 2008, from http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=46&abstractID=20371
24. Shahinian, V.B., Kuo, Y.F., Freeman, J.L., Orihuela, E., & Goodwin, J.S. (2005). Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer, 103(8), 1615-1624.
25. Sizer, F.S., & Whitney, E.N. (2000). Nutrition: Concepts and controversies (8th ed.). Belmont, CA: Wadsworth/Thompson Learning.
26. Smith, J.C., Bennett, S., Evans, L.M., Kynaston, H.G., Parmar, M., Mason, M.D., et al. (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism, 86(9), 4261-4267.
27. Smith, M.R. (2007). Androgen deprivation therapy for prostate cancer: New concepts and concerns. Current Opinion in Endocrinology, Diabetes, and Obesity, 14(3) 247-254.
28. Smith, M.R., Finkelstein, J.S., McGovern, F.J., Zietman, A.L., Fallon, M.A., Schoenfeld, D.A., et al. (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 87(2), 599-603.
29. Smith, M.R., Lee, H., & Nathan, D.M. (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 91(4), 1305-1308.
30. Surveillance, Epidemiology, and End Results Program. (2007). SEER*Stat Database: Incidence-SEER 17 Registries Limited-Use (1973-2005) [Data file]. Retrieved August 26, 2008, from http://seer.cancer.gov/data
31. Turner, A.M. (2007). Cardiovascular risk: Motivating behaviour change to reduce it. Practice Nurse, 34, 35-40.